POSA110 Cost-Effectiveness Analysis of Pembrolizumab Versus Brentuximab Vedotin (BV) in Adult and Paediatric Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma in France
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.254
https://www.valueinhealthjournal.com/article/S1098-3015(21)02049-0/fulltext
Title :
POSA110 Cost-Effectiveness Analysis of Pembrolizumab Versus Brentuximab Vedotin (BV) in Adult and Paediatric Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02049-0&doi=10.1016/j.jval.2021.11.254
First page :
Section Title :
Open access? :
No
Section Order :
11028